




RealRate

PHARMACEUTICAL 2019

Northwest Biotherapeutics INC
Rank 336 of 361



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Northwest Biotherapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Northwest Biotherapeutics INC compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 6.0% points. The greatest weakness of Northwest Biotherapeutics INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 168% points.

The company's Economic Capital Ratio, given in the ranking table, is 73%, being 176% points below the market average of 250%.

Input Variable	Value in 1000 USD
Assets, Current	23,798
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	69,840
Liabilities, Non-Current	1,986
Other Assets	761
Other Compr. Net Income	1,597
Other Expenses	4,504
Other Liabilities	0
Other Net Income	8,963
Other Revenues	412
Property and Equipment	108
Research and Development	18,154
Selling, General and Administrative Expense	22,511

Output Variable	Value in 1000 USD
Assets	24,667
Liabilities	71,826
Expenses	45,169
Revenues	412
Stockholders Equity	-47,159
Net Income	-35,794
Comprehensive Net Income	-34,996
BaseVar	76,317
ECR before LimitedLiability	-286%
Economic Capital Ratio	73%